Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages 2457-2466

  Idorn, Thomas ^a   Knop, Filip K ^a,b   Jørgensen, Morten B ^a   Christensen, Mikkel ^a   Holst, Jens J ^b   Hornum, Mads ^a   Feldt Rasmussen, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE (1-42); GASTRIC INHIBITORY POLYPEPTIDE (3-42); GASTRIC INHIBITORY POLYPEPTIDE 1(9-36)AMIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; PLACEBO; SITAGLIPTIN; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE (1 42); GLUCAGON LIKE PEPTIDE 1 (7 36)AMIDE; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; PEPTIDE FRAGMENT; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENMARK; DOUBLE BLIND PROCEDURE; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; END STAGE RENAL DISEASE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INSULIN BLOOD LEVEL; MALE; METABOLIC CLEARANCE RATE; OBSERVATIONAL STUDY; PILOT STUDY; PLASMA HALF LIFE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUME OF DISTRIBUTION; BLOOD; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; DIET RESTRICTION; METABOLISM; MIDDLE AGED; PROTEIN DEGRADATION; RENAL REPLACEMENT THERAPY; URINE;

ADULT; BLOOD GLUCOSE; DENMARK; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEOLYSIS; PYRAZINES; RENAL DIALYSIS; TRIAZOLES;

EID: 84907291964     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3809     Document Type: Article

References (36)

1. Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahrén B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab. 2008; 295(4):E779-E784.
2. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995; 56(2):117-126.
3. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000;85(10):3575-3581.
4. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585-3596.
5. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829-835.
6. Hupe-Sodmann K, Göke R, Göke B, et al. Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides. 1997;18(5):625- 632.
7. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995; 58(3):149-156.
8. Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab. 2009;23(4):443-452.
9. Deacon C.F. , DanielsenP., KlarskovL., OlesenM., HolstJ.J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes2001;50(7):1588-1597.
10. Meier JJ, Nauck MA, Kranz D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53(3):654- 662.
11. Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab. 1992;74(2):379-384.
12. Ruiz-Grande C, Alarcón C, Alcantara A, et al. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res. 1993;25(12): 612- 616.
13. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept. 2005;128(2):117-124.
14. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271(3 Pt 1):E458-E464.
15. Jorde R, Burhol PG, Gunnes P, Schulz TB. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats. Scand J Gastroenterol. 1981;16(4):469- 471.
16. O'Dorisio TM, Sirinek KR, Mazzaferri EL, Cataland S. Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism. 1977; 26(6):651-656.
17. Sirinek KR, O'Dorisio TM, Gaskill HV, Levine BA. Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. Am J Surg. 1984;148(6):732-735.
18. Idorn T, Knop FK, Jørgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B. Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney Int. 2013;83(5):915-923.
19. Idorn T, Knop FK, Jørgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. Nephrol Dial Transplant. 2013;119-127.
20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-553.
21. PolyPeptide Group. Catalogue. http://www.polypeptide.com/ catalog/. (Accessed 9 May, 2013).
22. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide I in humans. Diabetes. 1994;43(4):535-539.
23. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88(6): 2706-2713.
24. Lindgren O, Carr RD, Deacon CF, et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab. 2011;96(8):2519-2524.
25. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia. 2007;50(4):797-805.
26. Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220-224.
27. Heptinstall RH. 1983 End-stage kidney and the effects of dialysis. In: Heptinstall RH, ed. Pathology of the kidney. Boston: Little Brown; 617- 626.
28. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 Suppl 1):S1-S266.
29. Takebayashi S. Sonographic evaluation of kidneys undergoing dialysis. Urol Radiol. 1985;7(2):69-74.
30. Alcazar AR. Electrolyte and acid-base balance disorders in advanced chronic kidney disease. Nefrologia. 2008;28 Suppl 3:87-93.
31. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48(9):1882-1890.
32. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36(11-12):761-765.
33. Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS. The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology. 1984;115(3):1011-1018.
34. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67(2):563-568.
35. Idorn T, Knop FK, Jørgensen M, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open. 2013;3(4):e002764.
36. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117(18):2340-2350.